Fresenius Medical Care AG & Co. KGAA (FMS) EPS Estimated At $0.61; Precision Drilling (PDS) Had 10 Bullish Analysts

February 15, 2018 - By Marguerite Chambers

Among 19 analysts covering Precision Drilling Corporation (NYSE:PDS), 10 have Buy rating, 0 Sell and 9 Hold. Therefore 53% are positive. Precision Drilling Corporation had 52 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Precision Drilling Corporation (NYSE:PDS) earned “Buy” rating by Cowen & Co on Friday, July 7. The company was maintained on Thursday, July 20 by Jefferies. The company was downgraded on Tuesday, September 12 by JP Morgan. The rating was downgraded by Scotia Capital on Friday, October 9 to “Sector Perform”. As per Tuesday, February 2, the company rating was downgraded by Raymond James. Tudor Pickering upgraded Precision Drilling Corporation (NYSE:PDS) on Tuesday, November 29 to “Buy” rating. The rating was maintained by Credit Suisse on Friday, September 4 with “Neutral”. On Monday, September 18 the stock rating was upgraded by PiperJaffray to “Overweight”. The company was upgraded on Wednesday, April 26 by Raymond James. The rating was initiated by Citigroup with “Neutral” on Wednesday, December 14. See Precision Drilling Corporation (NYSE:PDS) latest ratings:

27/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $4.25 Maintain
18/10/2017 Broker: Cowen & Co Rating: Buy New Target: $5.0 Maintain
16/10/2017 Broker: Jefferies Rating: Buy New Target: $4.5 Maintain
10/10/2017 Broker: Deutsche Bank Rating: Hold New Target: $4 Initiates Coverage On
18/09/2017 Broker: PiperJaffray Old Rating: Neutral New Rating: Overweight Upgrade
18/09/2017 Broker: Piper Jaffray Rating: Buy New Target: $4.25 Upgrade
14/09/2017 Broker: Cowen & Co Rating: Buy New Target: $5.0 Maintain
12/09/2017 Broker: JP Morgan Old Rating: Overweight New Rating: Neutral Downgrade
12/09/2017 Broker: J.P. Morgan Rating: Hold Downgrade
06/09/2017 Broker: Jefferies Rating: Buy New Target: $4.5 Maintain

Analysts expect Fresenius Medical Care AG & Co. KGAA (NYSE:FMS) to report $0.61 EPS on February, 28.They anticipate $0.02 EPS change or 3.17% from last quarter’s $0.63 EPS. FMS’s profit would be $356.92 million giving it 22.15 P/E if the $0.61 EPS is correct. After having $0.59 EPS previously, Fresenius Medical Care AG & Co. KGAA’s analysts see 3.39% EPS growth. The stock increased 2.04% or $1.08 during the last trading session, reaching $54.04. About 137,060 shares traded. Fresenius Medical Care AG & Co. KGAA (NYSE:FMS) has risen 11.17% since February 15, 2017 and is uptrending. It has underperformed by 5.53% the S&P500.

Among 8 analysts covering Fresenius Medical (NYSE:FMS), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Fresenius Medical had 17 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Fresenius Medical Care AG & Co. KGAA (NYSE:FMS) has “Buy” rating given on Tuesday, September 22 by Goldman Sachs. The stock of Fresenius Medical Care AG & Co. KGAA (NYSE:FMS) has “Buy” rating given on Thursday, March 17 by Nomura. As per Thursday, October 12, the company rating was maintained by RBC Capital Markets. RBC Capital Markets maintained the shares of FMS in report on Monday, August 7 with “Hold” rating. As per Monday, December 11, the company rating was downgraded by Morgan Stanley. The firm has “Buy” rating by SunTrust given on Wednesday, December 20. The rating was maintained by RBC Capital Markets with “Hold” on Wednesday, July 5. RBC Capital Markets maintained the shares of FMS in report on Tuesday, May 30 with “Hold” rating. The rating was maintained by SunTrust with “Buy” on Thursday, November 2. RBC Capital Markets maintained Fresenius Medical Care AG & Co. KGAA (NYSE:FMS) rating on Thursday, November 2. RBC Capital Markets has “Hold” rating and $50.0 target.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. The company has market cap of $31.62 billion. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure. It has a 23.27 P/E ratio. The firm also develops, makes, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, and endovascular specialty, as well as hospitalist and intensivist, and medical cost management services.

The stock increased 4.91% or $0.16 during the last trading session, reaching $3.42. About 3.82 million shares traded or 28.14% up from the average. Precision Drilling Corporation (NYSE:PDS) has declined 14.25% since February 15, 2017 and is downtrending. It has underperformed by 30.95% the S&P500.

Precision Drilling Corporation provides oil and natural gas drilling and related services and products. The company has market cap of $1.00 billion. The firm operates in two divisions, Contract Drilling Services, and Completion and Production Services. It currently has negative earnings. The Contract Drilling Services segment offers onshore well drilling services to exploration and production companies in the oil and natural gas industry.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>